摘要
CRISPR-Cas技术直接用于编辑人类胚胎之临床研究的前提是要具备可接受的风险-收益比。利益相关方要避免如同基因治疗临床试验和胚胎干细胞治疗初期那样对潜在疗效的夸大和误判,采取有效措施减少脱靶效应及其他难以预测的后果。不过,在当前阶段对非医学目的设计婴儿的担忧,不是限制那些出于治疗目的之人类胚胎基因编辑临床研究的主要理由。国家应尽快酝酿制定CRISPR-CAS技术临床应用的伦理准则、技术标准和监管细则。
The acceptable risk-benefit ratio is one fundamental ethical requirement for approval of CRISPR-Cas germline editing clinical research on human embryos.Due to the lessons obtained from the early development of gene therapy clinical trial and embryonic stem cell therapy,stakeholders should avoid the hype and misuse of CRISPR-Cas germline editing from the early beginning.At same time,scientists should take measures to reduce the risks of off-target effect and other incidental consequences.However,the author argues that non-medical purpose of design genome babies by using CRISPR-Cas is not a good reason against its clinical implication.China ought to establish its model regulatory framework to meet the technical and ethical demands specific to these clinical trials.
出处
《科学与社会》
CSSCI
2016年第3期12-21,共10页
Science and Society
